Balancing Bleeding Risk vs. Thrombotic Risk to Define Dual Antiplatelet Therapy Duration

Patients who undergo complex angioplasty are at higher ischemic risk, but only benefit from extended dual antiplatelet therapy if there are no factors for high bleeding risk. These data suggest that the bleeding risk must weigh more than the ischemic risk on the determination of dual antiplatelet therapy duration.

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregaciónComplex angioplasty is associated with higher ischemic risk, which can be partially mitigated by extending the duration of dual antiplatelet therapy. In any case, there is a bleeding risk and it may be high, so the question regarding which risk should be prioritized is a daily discussion among interventional cardiologists, who see bleeding as a complication for patients and not for them (they only care about thrombosis). In the meantime, clinical cardiologists are caught in the middle. They make the decision, but, sometimes, their scales are not well calibrated.

 

Complex angioplasty was defined as ≥3 stents implanted and/or ≥3 lesions treated, bifurcation with 2 stents, stent length >60 mm, and/or chronic total occlusions. Risk was considered high when the PRECISE-DAPT score was >25 or when it was not below that. Patients were stratified according to these characteristics and randomized to short- or long-term dual antiplatelet therapy.


Read also: Clinical and Economic Costs Compete in the De-Escalation of Antiplatelet Therapy.


There were 14,963 total patients from 8 randomized trials, among whom 3118 patients underwent complex angioplasty with high ischemic risk, but did not experience bleeding events.

 

Extending dual antiplatelet therapy in patients with low bleeding risk was beneficial because it reduced ischemic events in both complex (absolute risk difference: -3.86%; 95% confidence interval [CI]: -7.71 to +0.06) and noncomplex angioplasty patients (absolute risk difference: -1.14%; 95% CI: -2.26 to -0.02). However, that did not happen in patients with high bleeding risk, beyond angioplasty complexity.


Read also: What is the best antiplatelet in PCI to vein grafts?


The bleeding risk according to the Thrombolysis In Myocardial Infarction (TIMI) scale was increased with extended dual antiplatelet therapy only in patients with high bleeding risk (>25 PRECISE-DAPT score), regardless of angioplasty complexity.

 

Conclusion

Patients who undergo complex angioplasty can benefit from extended dual antiplatelet therapy only if they present low bleeding risk. At the crossroads, decisions on dual antiplatelet therapy duration should prioritize the bleeding risk over the ischemic risk.

 

Original title: Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.

Reference: Francesco Costa et al. J Am Coll Cardiol 2019;73:741-54.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....